Bayer reports more positive PhIII data for hypertension contender; Shire commits $22M to rare disease alliance in Italy;

Conversations on Twitter :

 @FierceBiotech: Industry Voices: Biosimilars and Trade Secrets. Feature | Follow @FierceBiotech

 @JohnCFierce: ZS Pharma down in Fort Worth raised $46M in venture funds for clinical trial of kidney, liver disease drug. | Follow @JohnCFierce

 @RyanMFierce: Radius has set its biotech IPO range $8.50-$10.50. Will it hit its price target and keep the streak alive? More | Follow @RyanMFierce

> After reporting upbeat Phase III results in PAH, Bayer has reported success in a late-stage study for patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or those with persistent or recurrent pulmonary hypertension (PH) after surgery with the same experimental drug, riociguat. Release

> Eyeing the growing healthcare market in China, MicuRx Pharmaceuticals, a developer of antibiotics and Shanghai MengKe Pharmaceuticals have formed a joint venture to commercialize a candidate dubbed MRX-I in the Asian country. Item

> Bristol-Myers Squibb ($BMY) fell to a third-quarter loss in part because of its failed Hepatitis C program involving assets acquired in its $2.5 billion buyout of Inhibitex.  Article

> Shire ($SHPG) has pledged $22 million over 5 years to support an alliance with a Italian biomedical charity, the Fondazion Telethon, to research new therapies for rare diseases. Release

> Pearl Therapeutics (a 2011 Fierce 15 company) has wrapped up a final Phase IIb study of its lead COPD therapy called PT003 and selected a dose for late-stage development of the experimental treatment. Release

> Cambridge, MA-based biotech Radius Health, which is developing an osteoporosis therapy, has set a price range of $8.50 to $10.50 for its initial public offering. Report

Pharma News

@FiercePharma: More pain for Big Pharma sales: Lilly's drop 11%, earnings fall short. Not as bad as BMS, though. More | Follow @FiercePharma

> Pharma wheels and deals in Europe as austerity wears on. Story

> GOP or Dem? Some pharma donors don't hedge their bets. Article

> BMS results crater on 96% drop in Plavix sales. News

Medical Device News

 @FierceMedDev: The FDA says it will focus more on quality in the device approval process. What that means may be an open question. More | Follow @FierceMedDev

 @MarkHFierce: A medical device regulatory scandal erupts in Great Britain. Report | Follow @MarkHFierce

 @DamianFierce: Thermo Fisher beats the Street again on soaring diagnostics sales. More | Follow @DamianFierce

> St. Jude's heart-plug future hinges on study data. Story

> EU notified bodies accused of improperly competing for device business. Article

> Bard nabs Neomend for $140M. News

> Zoll Medical launches Japan division. Report

Drug Delivery News

> Fuse Science rolls out roll-on delivery. News

> Biotecnol and PolyTherics team up to develop drug conjugates. Story

> Antibiotic Trojan horse for cholera may be possible. Item

> Oral flu vaccine melts in your mouth. More

Biomarkers News

> Genes might not be the key to antidepressant success after all. Story

> Blood test could predict breast cancer 20 years early. More

> Blood antibody pinpoints deadly preeclampsia. Article

> Researchers seek new pancreatic cancer biomarkers. Item

And Finally… A new Harvard study highlights to role of genetics in the placebo effect, which has befuddled drug developers for decades. Item

Suggested Articles

With a new research team, outlook and more than a little help from the tech world, GSK has been quietly going about shoring up its pipeline.

The World Health Organization has called out Big Pharma for its dearth of antibiotic innovation amid a growing threat of antimicrobial resistance.

The trial hit its primary endpoint by the time of an interim analysis, enabling Chi-Med to stop the study and start work on a filing for approval.